LLPC geassocieerde studies

Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B)

previously untreated MCL, high risk. At least one High risk MCL feature, defined as I. MIPI-c high intermediate (HI) or high (H) risk (i.e. high-risk MIPI irrespective of Ki-67 or intermediate risk MIPI and Ki-67>=30% (Ki-67 based on local pathology) 
and/or 
II. TP53 deletion and /or mutation and/or TP53 overexpression by immunohistochemistry (> 50% of lymphoma cells), sequencing (mutations and deletions) or FISH

KT-US-484-0136:  An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma.

2 cohorten:
Cohort 1: R/R DLBCL of Folliculair lymfoom gr3b na 2 lijnen systeemtherapie of na 1 lijn systeemtherapie in transplant-ineligible patienten. Cohort voor CART-exposed patienten is voorlopig dicht.   
Cohort 2: Folliculair lymfoom gr 1-3a en marginale zone lymfoom na 2 of meer lijnen systeemtherapie (inclusief een anti CD20 antilichaam) - open

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton’s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies

R/R CLL/SLL with CNS involvement

In- en exclusiecriteria
Advertentie tekst (goedgekeurd door EC)